COVID grantUpdated COVID Grant Opportunities

April 10, 2020

FUNDING OPPORTUNITIES RELATED TO COVID-19 and the SARS-CoV-2 PANDEMIC

 

READ HERE FOR LATEST UPDATES FROM JHU

 

NIH Funding Opportunities for COVID Grants

https://grants.nih.gov/grants/natural_disasters/corona-virus.htm

NOT-AI-20-034

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome

National Institute of Allergy and Infectious Diseases (NIAID)

NOT-AI-20-040

Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019

National Institute of Allergy and Infectious Diseases (NIAID)

NOT-GM-20-025

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19)

National Institute of General Medical Sciences (NIGMS)

NOT-AI-20-030

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of General Medical Sciences (NIGMS)

NOT-HL-20-757

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

National Heart, Lung, and Blood Institute (NHLBI)

NOT-DA-20-047

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

National Institute on Drug Abuse (NIDA)

NOT-TR-20-011

Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

National Center for Advancing Translational Sciences (NCATS)

NOT-GM-20-025

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

National Institute of General Medical Sciences (NIGMS)

 

NIH Guidance Related to COVID grants

https://www.youtube.com/watch?v=V5-Ry-2uGxs&feature=youtu.be

 

Proposal Submission & Award Management

Human Subjects & Clinical Trials

Animal Welfare

Peer Review

  • Based on NIH Guidance on Travel and Meetings , in-person NIH peer review meetings are being held in alternate formats. Scientific review officers will be in contact with peer reviewers about these changes.

 

BARDA SPECIFIC FUNDING for COVID grants

https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view?keywords=BAA-20-100-SOL-0002%20&sort=-relevance&index=&is_active=true&page=1

2020 NIAID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2020-1 – COVID-19 Proposals

The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.

The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest until further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 will be accepted. While we regret this action, it is required to focus BARDA’s efforts on the immediate need. 

 

The latest BARDA BAA is amendment 13 posted on March 4, 2020.

All Areas of Interest are suspended except:

  1. AOI 7.7.1 Diagnostic Assay for human coronavirus using existing FDA-cleared platforms,
  2. AI 7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
  3. AOI 7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)
  4. AOI 8.3 COVID-19 Vaccine,
  5. AOI 9.2 COVID-19 Therapeutics,
  6. AOI 9.3 Immunomodulators or therapeutics targeting lung repair, and
  7. AOI 9.5 Pre-exposure and Post-exposure Prophylaxis,
  8. AOI 10 Respiratory Protective Devices,
  9. AOI 11 Ventilators. 

BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

NSF FUNDING for COVID grants

https://www.nsf.gov/news/special_reports/coronavirus/

Research on Coronavirus (COVID-19)

 

 Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

March 25, 2020

Dear Colleagues:

The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential topositively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

 Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research(SBIR) and Small Business Technology Transfer (STTR) Phase I Program

DOD COVID Grants

Congressionally Directed Medical Research Programs

 COVID-19 FAQs for Grant Applicants and Recipients (Version 2, March 25, 2020)

 

The Air Force

ALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM X20.R SBIR COMMERCIAL SOLUTIONS OPENING (CSO) AF VENTURES DIRECT TO PHASE II

 

Classification

  • Original Set Aside: Total Small Business Set-Aside (FAR 19.5)
  •  
  • Product Service Code: AD92 – R&D- DEFENSE OTHER: OTHER (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)
  • NAICS Code: 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
  • Place of Performance:

Description

The Air Force (AF) invites small business firms to submit proposals under this CSO for the Small Business Innovation Research (SBIR) Program.  Firms with the capability to conduct research and development (R&D) in the AF-related topics described in Section 10.1 and to commercialize the results of that R&D are encouraged to participate.  Note that this solicitation includes only one type of effort, Direct-to-Phase II. 

This CSO seeks innovative, commercial technologies proposed to create new AF solutions or potential new capabilities fulfilling requirements, closing capability gaps, or providing potential technological advancements.  This CSO may result in the award of prototype projects, which include not only commercially available technologies fueled by commercial or strategic investment, but also concept demonstrations, pilots, and agile development activities incrementally improving commercial technologies, existing Government-owned capabilities, or concepts for broad defense application(s).

Attachments/Links

Download All Attachments/Links

Contact Information

Contracting Office Address

  • STE 209 CP 937-999-1758 711 E MONUMENT ST
  • DAYTON , OH 45402-1320
  • USA

Primary Point of Contact

Secondary Point of Contact

Focus Area 5: Medical

Objective: This focus area aligns with the Medical sub-OPT to determine small businesses with existing or advanced product, service or solutions development potentially meeting identified COVID-19 medical capability gaps. The goal is to identify known medical deficiencies and gaps, matched with small business solutions able to deploy rapidly after funding agreement awards.

Approach 5a. Air & Surface Cleansing: Reduce contaminant loads in environments where Airmen operate to decrease the COVID-19l transmission likelihood, including patient transfer mobility aircraft.

  • Antiviral Surface Coatings — COVID-19 has evidenced remaining on untreated surfaces for up to three days. Contact with disinfectant needs 30 seconds to 10 minutes to be effective. The surface chemistries developed would provide ability to ‘bind’ COVID-19 to disinfectants, proving far more effective than ‘wiping’ surfaces.

 

Approach 5b. COVID-19 Testing & Management:

  • Field Deployable COVID-19 Test Kits — Ruggedized COVID-19 test kits deployable to field environments lacking refrigeration, and delivering local test results.
  • Dual-Patient Ventilator Modification — Adaptation of currently fielded ventilators to enable single machines to service two or more patients simultaneously.

 

Approach 5c. COVID-19 Medical Supply Chain:

  • Additive Manufacturing ISO Medical Supply Chain — Leveraging AF additive manufacturing capacity to develop and print supplies on demand to meet DoD needs and supports civil authorities missions.
  •  

Need Assistance with your COVID grant?  Look no further than Dr. Bilello

Facebooktwitterlinkedinmail
0 Comments

Leave a reply

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2020 ScienceDocs Inc.

Log in with your credentials

Forgot your details?